Fisher Asset Management
VRDN icon

Fisher Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Fisher Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2M Sell
1,750,850
-17,445
-1% -$281K 0.01% 294
2026
Q1 		$34.6M Sell
1,768,295
-11,989
-0.7% -$356K 0.01% 272
2025
Q4 		$55.4M Buy
1,780,284
+579,058
+48% +$15.9M 0.02% 223
2025
Q3 		$25.9M Buy
1,201,226
+691,267
+136% +$12.5M 0.01% 290
2025
Q2 		$7.13M Sell
509,959
-27,065
-5% -$367K ﹤0.01% 438
2025
Q1 		$7.24M Buy
537,024
+18,997
+4% +$324K ﹤0.01% 452
2024
Q4 		$9.93M Buy
518,027
+23,103
+5% +$502K ﹤0.01% 432
2024
Q3 		$11.3M Buy
494,924
+99,427
+25% +$1.63M ﹤0.01% 407
2024
Q2 		$5.15M Buy
395,497
+6,410
+2% +$88.7K ﹤0.01% 486
2024
Q1 		$6.81M Buy
+389,087
New +$7.54M ﹤0.01% 464

Other funds holding VRDN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Fisher Asset Management's VRDN Position: Q2 2026 in Review

Fisher Asset Management reduced its Viridian Therapeutics (VRDN) stake by 0.99% in Q2 2026, selling an estimated $281K and leaving 1,750,850 shares worth $32.2M. The position accounts for 0.01% of the portfolio, ranked #294.

Fisher Asset Management first reported a position in VRDN in Q1 2024 and has held it in 10 quarters since. The position peaked at $55.4M in Q4 2025. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Fisher Asset Management held 1,750,850 shares of Viridian Therapeutics worth $32.2M as of Q2 2026.
  • Fisher Asset Management sold 17,445 Viridian Therapeutics shares in Q2 2026, an estimated $281K.
  • Viridian Therapeutics made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #294 holding.
  • Fisher Asset Management first reported a position in Viridian Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Fisher Asset Management's Viridian Therapeutics position peaked at $55.4M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.